Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2075)	4/16/2004 12:14:03 PM
From: Icebrg	Read Replies (1) \| Respond to of 3044

ASCO abstracts. The ASCO abstracts are now available on-line at ASCO's site. Well, we are really talking about mini-abstracts as it is only the headings. But still. It is possible to get some ideas about what is going to be presented. As far as Velcade is concerned there appears to be quite "a lot" coming out on Velcade and solid tumors. First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM). Details ... Poster Number: F6 Abstract No: 6551 Presenter: Sundar Jagannath, MD PAD therapy (bortezomib, doxorubicin and dexamethasone) for untreated multiple myeloma (MM). Details ... Poster Number: F5 Abstract No: 6550 Presenter: James D. Cavenagh, MD Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Details ... Poster Number: L9 Abstract No: 4654 Presenter: Robert Dreicer, MD Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM). Details ... Poster Number: 18 Abstract No: 7526 Presenter: Susan M. Geyer, PhD Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial. Details ... Poster Number: W11 Abstract No: 7145 Presenter: James P. Stevenson, MD Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results. Details ... Poster Number: T6 Abstract No: 7107 Presenter: Michael P. Fanucchi, MD The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study. Details ... Poster Number: T5 Abstract No: 7106 Presenter: Angela M. Davies, MD Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study. Details ... Poster Number: J9 Abstract No: 3591 Presenter: Tomislav Dragovich, MD, PhD Effects of the 26S proteasome inhibitor, bortezomib, on BCL-2 in small cell lung cancer: Implications for SWOG-0327. Details ... Poster Number: AA11 Abstract No: 9560 Presenter: Melinda M. Mortenson, MD Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). Details ... Poster Number: J4 Abstract No: 6582 Presenter: Owen A. O'Connor, MD Selective agnostic monoclonal antibodies to the TRAIL receptors R1 and R2 induce cell death and potentiate the effect of chemotherapy and bortezomib in primary and cultured lymphoma cells. Details ... Poster Number: K6 Abstract No: 6595 Presenter: Georgios V. Georgakis, MD Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphomas (NHL). Details ... Poster Number: J3 Abstract No: 6581 Presenter: Andre Goy, MD Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. Details ... Abstract No: 6511 Presenter: Paul Gerard Guy Richardson, MD Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study. Details ... Poster Number: B11 Abstract No: 2057 Presenter: Syma Iqbal, MD Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. Details ... Poster Number: M2 Abstract No: 3052

To: Icebrg who wrote (2075)	4/22/2004 3:48:49 PM
From: Icebrg	Respond to of 3044

Neill Giese SGX Appoints Neill Giese, Ph.D. as Senior Vice President of Drug Development SAN DIEGO, April 22 /PRNewswire/ -- SGX (Structural GenomiX, Inc.) announced today the appointment of Neill Giese, Ph.D. as senior vice president of drug development. Dr. Giese will be responsible for all translational biology, and pre-clinical and clinical development at SGX. "Neill's wealth of experience with developing small molecule cancer therapies will be instrumental in driving our drug discovery programs into human trials and through the clinic," said Tim Harris, Ph.D., chief executive officer of SGX. "We are very excited to have Neill join the SGX team." Dr. Giese has over 14 years of experience in drug discovery and development ranging from target identification to clinical trials. He joins SGX from Millennium Pharmaceuticals where he played a lead role in the discovery and development of MLN518, an oral small molecule kinase inhibitor currently being studied in Phase II clinical trials for the treatment of acute myelogenous leukemia. He completed his postdoctoral work in molecular oncology under Stuart Aaronson's direction at the National Cancer Institute at the National Institutes of Health. Dr. Giese received his Ph.D. from the University of Arizona in Pharmacology/Toxicology and his B.S. in Pharmacy from Oregon State University. [MLN518 not of interest any more?]